Please assess the completion status of the following clinical trial:

Trial Title: Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years at the time of signing the informed consent form and either male or female.~* Diagnosis of RA according to the 1987 ACR classification criteria OR 2010 ACR/EULAR classification criteria at least 6 months prior to screening.~* Patients with persistent RA disease activity whilst being treated with an initial TNFi agent on a background MTX up to 20-25 mg/week for at least 12 weeks defined according to SIR and EULAR guidelines as: primary non-response: failing to improve DAS28 by ≥ 1.2 or failing to achieve DAS28 ≤ 3.2 within the first three to six months of starting the initial TNFi; secondary non-response: determined by physician decision with evidence of flare and deterioration in DAS28 of ≥ 1.2.~* Methotrexate (MTX) dose stable for 28 days prior to screening.~* Patients on NSAIDs and / or corticosteroids must remain on an unchanged regimen for at least 28 days prior to study drug administration.~* The patient must be able to comply with the study visit schedule and other protocol requirements.~* The patient understands the purpose of the study and is able and willing to sign the informed consent form, according to ICH/GCP.~* Signed written informed consent for biological analysis.~* Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to start of trial. Women of childbearing potential and male patients must be willing to practice acceptable methods of contraception during treatment and for 6 months (female patients) and 3 months (male patients) after discontinuation of treatment.~Exclusion Criteria:~* Patients who have previously received more than 1 TNFi drug OR any other biological therapy.~* Patients with inflammatory joint disease of different origin or any arthritis with onset prior to 16 years of age.~* Patients taking any disease-modifying antirheumatic drug (DMARDs) (e.g. all except methotrexate). Discontinuation must occur at least 28 days prior to study treatment start.~* History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug.~* Known hypersensitivity to any active substance or excipients of study drug.~* Pregnancy or breast feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Switching strategy (Type: EXPERIMENTAL): Tocilizumab \[RoActemra®\] \[ATC: L04AC07\] 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
- Cycling strategy (Type: ACTIVE_COMPARATOR): 1. Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab OR~2. Infliximab, adalimumab, golimumab or certolizumab if initial failure to the receptor fusion protein, etanercept.

Based on this trial design, predict the completion outcome and termination type (if applicable).